Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.

@article{Moliterno1995EffectOP,
  title={Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.},
  author={David J Moliterno and Robert M. Califf and Frank V. Aguirre and K. C. Anderson and Kristina N. Sigmon and Harlan F. Weisman and Eric J. Topol},
  journal={The American journal of cardiology},
  year={1995},
  volume={75 8},
  pages={559-62}
}
The activated clotting time (ACT) has been used during percutaneous transluminal coronary angioplasty (PTCA) to monitor the extent of thrombin inhibition and anti-coagulation from heparin in an attempt to minimize untoward thrombotic events and hemorrhagic complications. With the introduction of potent platelet inhibitors, such as the chimeric monoclonal… CONTINUE READING